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Simple Summary: Although sunitinib is a standard first-line treatment for metastatic renal cell
carcinoma, little is known about the predictive factors of sunitinib-induced dose-limiting toxicity
in Asian populations. Thus, the aim of this study was to determine whether body composition
features significantly associated with sunitinib toxicity in Western populations might predict early
dose-limiting toxicity in Korean patients with metastatic renal cell carcinoma. The administration
of sunitinib at a fixed dose has the advantage of simplicity but does not consider inter-individual
variations, resulting in a high drug toxicity. As high-resolution computed tomography images of
patients with cancer are readily available using the body composition, mainly visceral adipose tissue,
individualized sunitinib dosage could be feasible in real-world clinical practice, according to this
study. Using the appropriate sunitinib dosage based on body composition, visceral adipose tissue
index, would reduce sunitinib toxicity.
Abstract: Sunitinib is a first-line treatment for metastatic renal cell carcinoma (mRCC). Little is
known about the predictive factors of sunitinib-induced dose-limiting toxicity (DLT) in Asian
populations. We investigated whether body composition predicts sunitinib-induced DLT.
We retrospectively reviewed sunitinib-treated Korean patients with clear cell mRCC from eight
institutions. Body composition was measured using computed tomography. DLT was defined as any
adverse event leading to dose reduction or treatment discontinuation. Univariate analysis was used
to compare body composition indices, and logistic regression analyses were performed for factors
predicting early DLT. Overall, 111/311 (32.5%) of patients experienced DLT. Significant differences
were observed in the subcutaneous adipose tissue index (SATI; p = 0.001) and visceral adipose tissue
index (VATI; p < 0.001) between patients with and without DLT. Multivariate analyses revealed that
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VATI (odds ratio: 1.013; p = 0.029) was significantly associated with early DLT. Additionally, 20% of
patients who had a body mass index (BMI) greater than 23 kg/m2 and a low VATI experienced DLT,
whereas 34.3% of the remaining groups had DLT (p = 0.034). Significant differences were observed
for median progression-free survival (13.0 vs. 26.0 months, respectively; p = 0.006) between patients
with low and high VATI. Visceral adiposity was a significant predictor of sunitinib-associated DLT
and survival. Patients with a low VATI and a BMI greater than 23 kg/m2 experienced lower DLTs.
Keywords: dose-limiting toxicity; obesity; renal cell carcinoma; sunitinib; visceral adiposity
1. Introduction
Renal cell carcinoma (RCC) is the most common kidney cancer, and clear cell RCC (cc-RCC)
is the most prevalent type worldwide [1]. The incidence and mortality rates are rising 2–3% per
decade; around 30% of patients are diagnosed in the metastatic stage, with <10% surviving more than
5 years [2,3]. For advanced metastatic RCC (mRCC), sunitinib (Sutent; Pfizer), a multikinase inhibitor
with antiangiogenic properties, is a standard first-line treatment option [4,5].
Common toxic effects of sunitinib are diarrhea, hand-foot syndrome, fatigue, and hypertension,
which limit the full dose of sunitinib and account for dose reduction and treatment termination in
32% and 8% of patients, respectively [4]. Little is known about the factors that predict sunitinib
toxicity in RCC [6]. There is substantial inter-individual variability in sunitinib pharmacokinetics,
which is partly explained by the varying cytochrome P450 (CYP450) expression levels and CYP3A5
polymorphisms [7,8]. This might identify some patients prone to toxicity-related dose reductions that
cannot be routinely assessed in the clinic [6,9].
Body composition, including skeletal muscle (SM), adipose tissue, and fat-free mass, is a prognostic
factor in cancer and is reported to be superior to conventional measures of body size, such as weight,
body mass index (BMI), and body surface area (BSA), for drug dosage prediction [6,10]. Patients with
mRCC have diverse BMIs (15.2–38.1 kg/m2), resulting in differences in drug plasma concentration
and metabolism, leading to different toxicity rates. Nevertheless, sunitinib is administered at a fixed
dosage of 50 mg daily for 28 days, followed by a 14-day break, during which body composition is not
accounted for [6].
Previous studies have demonstrated how body composition relates to sunitinib toxicity in Western
populations [6,9]; however, only one study has been performed in Asian populations, which is
inadequate to analyze all body composition features. Therefore, we determined whether body
composition features significantly associated with sunitinib toxicity in Western populations might
predict early dose-limiting toxicity (DLT) in Korean patients with mRCC.
2. Results
2.1. Patient Characteristics
We identified 311 patients with cc-mRCC that received sunitinib as a first-line therapy. The baseline
characteristics of these patients are presented in Table 1. The median BMI was 23.5 kg/m2, and 3.5% of
patients were classified as underweight. Collectively, 76.8% of tumors were classified as high-grade.
Cancers 2020, 12, 3602 3 of 11
Table 1. Baseline characteristics of the patients treated with sunitinib.
Characteristics Male (n = 251) Female (n = 60) Total (n = 311) p
Age, median (range) * (y) 62.0 (56.0–71.0) 64.0 (59.0–73.8) 63.0 (57.0–72.0) 0.134
Weight, median (range) * (kg) 69.0 (61.8–75.7) 56.5 (50.6–60.8) 66.8 (58.0–74.7) <0.001
BMI, median (range) * (kg/m2) 23.7 (21.8–25.8) 22.9 (21.6–25.2) 23.5 (21.8–25.7) 0.260
Underweight (BMI < 18.5) 7 (2.8%) 4(6.7%) 11 (3.5%)
0.112
Normal weight (18.5 ≤ BMI ≤ 24.9) 158 (62.9%) 41 (68.3%) 199 (64.0%)
Overweight (25 ≤ BMI ≤ 29.9) 77 (30.7%) 11 (18.3%) 88 (28.3%)
Obese (30 ≤ BMI) 9 (3.6%) 4 (6.7%) 13 (4.2%)
ECOG PS, n (%)
0–1 239 (95.2%) 56 (93.3%) 295 (94.9%)
0.522
≥2 12 (4.8%) 4 (6.7%) 16 (5.1%)
Number of metastatic sites, n (%)
1 106 (42.2%) 23 (38.3%) 129 (41.5%)
0.589
2 78 (31.1%) 24 (40.0%) 102 (32.8%)
3 49 (19.5%) 11 (18.3%) 60 (19.3%)
≥4 18 (7.2%) 2 (3.3%) 20 (6.4%)
Metastatic sites, n (%)
Lung 194 (40.6%) 39 (34.5%) 233 (39.4%)
0.800
Liver 44 (11.5%) 11 (48.7%) 55 (9.3%)
Bone 70 (14.6%) 19 (16.8%) 89 (15.1%)
Brain 15 (3.1%) 3 (2.7%) 18 (3.0%)
Others 155 (32.4%) 41 (36.3%) 196 (33.2%)
Early DLT, n (%)
Present 73 (29.1%) 28 (46.7%) 101 (32.5%)
0.009Absent 178 (70.9%) 32 (53.3%) 210 (67.5%)
L3 Area, median (range) * (cm2)
SAT 98.5 (71.6–129.7) 150.2 (123.4–177.6) 110.9 (75.5–145.9) <0.001
VAT 105.4 (56.0–150.7) 69.8 (43.7–115.2) 95.4 (51.1–146.4) 0.009
SM 145.1 (130.7–160.9) 98.2 (90.0–106.2) 139.6 (114.2–155.3) <0.001
L3 Index, median (range) *
(cm2/m2)
SATI 34.5 (24.1–46.2) 62.5 (48.6–72.0) 38.1 (26.0–55.2) <0.001
VATI 36.1 (18.6–52.1) 30.0 (17.9–46.5) 34.3 (18.5–51.7) 0.381
SMI 50.5 (45.4–55.1) 40.6 (36.9–43.9) 48.2 (42.2–54.1) <0.001
No. ISUP grade, n (%)
Low grade (1–2) 52 (20.7%) 20 (33.3%) 72 (23.2%)
0.037High grade (3–4) 199 (79.3%) 40 (66.7%) 234 (76.8%)
* Quartile range. Data are presented as medians (interquartile ranges) for continuous variables and as percentages
for categorical variables. p-values are from the chi-square test or Fisher’s exact test when categorical and Wilcoxon’s
test when continuous. BMI: body mass index; DLT: dose-limiting toxicity; ECOG PS: Eastern Cooperative Oncology
Group criteria performance status; SAT: subcutaneous adipose tissue; SATI: subcutaneous adipose tissue index;
SM: skeletal muscle; SMI: skeletal muscle index; VAT: visceral adipose tissue; VATI: visceral adipose tissue index.
2.2. Sunitinib Toxicity
During the first cycle of treatment, 101 patients (32.5%) experienced a DLT. Except in 38 cases,
patients experienced multiple grade 2 to 4 adverse events (AEs). The most frequent AEs were fatigue
(17.2%), hand-foot syndrome (17.0%), and thrombocytopenia (8.8%). Other AEs, including grade 1 and
2 gastrointestinal AEs and grade 2 and 3 hypertension, occurred frequently.
For all patients with DLTs, sunitinib was discontinued and resumed at a lower dose (37.5 mg).
Seven cases of permanent discontinuation were reported, owing to DLT during the first cycle of
treatment. Dose reduction in 12 patients did not sufficiently alleviate symptoms and their sunitinib
was discontinued.
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The comparison of anthropometric parameters between patients with or without early DLT is
summarized in Table 2. Those patients with a DLT had a significantly higher subcutaneous adipose
tissue (SAT) index (SATI; p = 0.001) and visceral adipose tissue (VAT) index (VATI; p < 0.001) than
patients without a DLT. A multivariate logistic regression analysis of indices that were significantly
associated with early DLT in univariate analysis revealed that only a patient’s VATI (odds ratio (OR):
1.013, 95% confidence interval (CI): 1.001–1.025, p = 0.029) was significantly associated with early DLT,
whereas their SATI (OR: 1.009, 95% CI: 0.998–1.020, p = 0.119) was not. Furthermore, parameters
associated with SM were not associated with early DLT, even in logistic regression analysis (skeletal
muscle index (SMI) (OR: 0.986, 95% CI: 0.959–1.015, p = 0.350); SM (OR: 0.995, 95% CI: 0.987–1.003,
p = 0.207)).
Table 2. Comparison of anthropometric measurements and demographic characteristics of patients
with or without early DLT.
Patients with Early DLT Patients without Early DLT
p
(n = 101) (n = 210)
Age (y) 65.2 (11.8) 62.8 (9.7) NS
Weight (kg) 67.3 (11.9) 67.1 (12.0) NS
BMI (kg/m2) 24.2 (3.3) 23.6 (3.3) NS
ECOG PS, n (%)
0–1 94 (93.1%) 201 (95.7%)
NS
≥2 7 (6.9%) 9 (4.3%)
L3 Area (cm2)
SAT 133.3 (71.2) 109.9 (59.2) 0.002
VAT 122.8 (85.8) 95.6 (61.2) 0.001
SM 133.6 (32.7) 138.2 (28.6) NS
L3 Index (cm2/m2)
SATI 49.0 (28.3) 39.4 (22.4) 0.001
VATI 44.1 (29.1) 33.6 (21.1) <0.001
SMI 47.7 (9.1) 48.6 (8.0) NS
No. of toxicities 3.5 (1.6) 1.7 (1.6) <0.001
Data are presented as means (standard deviations) for continuous variables and as percentages for categorical
variables. p-values are from the chi-square test or Fisher’s exact test when categorical and Student’s t-test when
continuous. BMI: body mass index; DLT: dose-limiting toxicity; NS: not significant; SAT: subcutaneous adipose
tissue; SATI: subcutaneous adipose tissue index; SM: skeletal muscle; SMI: skeletal muscle index; VAT: visceral
adipose tissue; VATI: visceral adipose tissue index.
Compared to patients with a low VATI, those with a high VATI experienced more DLTs (23.9% vs.
41.0%, respectively; p = 0.001) and AEs (p < 0.001) (Table 3).
Table 3. Comparison of the sunitinib toxicities between patients with a high/low visceral adipose
tissue index.
Low Visceral Adipose Tissue Index High Visceral Adipose Tissue Index
p
(n = 155) (n = 156)
Early DLT, n (%)
Present 37 (23.9%) 64 (41.0%)
0.001Absent 118 (76.1%) 92 (59.0%)
No. of toxicities, mean (SD) 1.5 (1.3) 3.1 (1.9) <0.001
Data are presented as means (standard deviations) for continuous variables and as percentages for categorical
variables. p-values are from the chi-square test or Fisher’s exact test when categorical and Student’s t-test when
continuous. DLT: dose-limiting toxicity.
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Moreover, DLT was reported in 20% of patients with a BMI greater than 23 kg/m2 and a low VATI
(<24 cm2/m2), whereas the remaining 34.3% of patients had DLTs (p = 0.034) (Figure 1).
 
Cancers 2020, 12, x; doi: FOR PEER REVIEW www.mdpi.com/journal/cancers 
Article 
Visceral Adiposity as a Significant Predictor of 
Sunitinib-Induced Dose-Limiting Toxicities and 
Survival in Patients with Metastatic Clear Cell Renal 
Cell Carcinoma 
 
Figure 1. Distribution of body mass index (BMI), visceral adipose tissue index (VATI), and early dose-
limiting toxicity (DLT) for sunitinib-treated patients. Symbols represent individual patients. The 
vertical dashed-line indicates the cut-off point for low VATI (<24 cm2/m2), and the horizontal dashed 
line indicates a BMI of 23 kg/m2. 
Figure 1. Distribution of body mass index (BMI), visceral adipose tissue index (VATI), and early
dose-limiting toxicity (DLT) for sunitinib-treated patients. Symbols represent individual patients.
The rtical dashed-line indicates the cut-off point for low VATI (< 4 cm2/m2), and the horizontal
dashed li e indic tes a BMI of 23 kg/m2.
2.3. Survival Analysis
The median cancer-specific survival (CSS) and progression-free survival (PFS) for the study
population were 27.0 months (95% CI: 20.8–33.2) and 19.0 months (95% CI: 14.3–23.7), respectively.
No significant differences were observed between patients with a low and high VATI regarding
the median CSS (23.0 months (95% CI: 13.5–32.5) vs. 36.0 months (95% CI: 23.3–48.7), respectively;
Figure 2A). However, a significantly shorter median PFS was observed in patients with a low VATI
than in patients with a high VATI (13.0 months (95% CI: 8.6–17.4) vs. 26.0 months (95% CI: 19.1–32.9),
respectively; p = 0.006; Figure 2B).
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Figure 2. Overall survival. (A) Cancer-specific survival in patients with high/low visceral adipose
tissue index (VATI). (B) Progression-free survival in patients with high/low VATI.
3. Discussion
This is the first large, nationwide, multi-institutional study to identify the relationship between
the VATI and early toxicity in Korean sunitinib-treated patients with cc-mRCC. Unlike other groups
that have shown an association between sarcopenia and sunitinib-induced DLT, we observed that
patients with a high VATI experienced significantly more DLTs than those with a low VATI during the
first cycle.
Four studies have evaluated the toxicity of antiangiogenic agents (sorafenib [10] and
sunitinib [6,9,11]) in patien s with mRCC. A meta-analysis of these studies demo strated that DLT is
more frequent in patients with a low SMI, with or without a BMI less than 25 kg/m2, than in patients
with a high SMI or a BMI greater than 25 kg/m2 [12]. However, most of these studies were performed
on Caucasians [6,9,10], and only one study focused on a Japanese population [11]. Despite being
the only study performed on an Asian population, Ishihara et al. did not evaluate if adipose tissues
affected the safety and tolerability of sunitinib. In the two studies that have evaluated the effect of
body composition on DLT in sunitinib-treated patients, the study populations exhibited a wide range
of BMI and muscularity—i.e., characteristics of “westernized” societies. These studies observed that
34.5% [6] and 21.3% [9] of atients were obese, whereas 4.2% f our patients were obese.
The cut-off values for BMI and sarcopenia have been ba ed on Western populations and sh uld be
adjusted for Asian populations. While the associations among BMI, body composition, and health risks
are different between these populations, the universal BMI criteria developed by the World Health
Organization (WHO) might be unsuitable for Asian populations [13]. Anuurad et al. re-categorized
BMI criteria for Asian populations as follows: underweight (<18.5 kg/m2), normal (18.5–22.9 kg/m2),
overweight (23–24.9 kg/m2), and obese (>25 kg/m2) [14]. Therefore, we used the BMI 23 kg/m2 cut-off
to classify a patient as overweight, instead of the metrics used in Western studies [9,10].
Our study showed that the 23 kg/m2-cut-off was more appropriate. When using the 23 kg/m2
cut-off, no DLT was reported in 20% of patients, w ereas, when using the 25 kg/m2 cut-off, n DLT
was rep rt i 27.3% of patients. The difference in the probabil ty of a DLT betw en patients who
simultaneously had a BMI higher than the cut-off point and a low VATI compared with the remaining
patients was significant (p = 0.034) when using the 23 kg/m2 cut-off, whereas the 25 kg/m2 cut-off
showed no significant difference. Therefore, we suggest using these parameters for Asian populations.
While comparing our results with those of Ishihara et al. would help to establish a standard cut-off for
Asian populations, the Ishihara et al. study did not report the values for adipose tissue.
Although there were no significant associations between SM parameters and DLT in our study,
previous studies have reported that SM, especially sarcopenia, is associated with DLT; however,
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these studies used different definitions of sarcopenia [6,9–11] or did not apply the international
definition, which might have resulted in bias. An international, standard definition for sarcopenia
needs to be established [15], and our results can contribute to international standard definitions by
considering the body composition of Asian populations.
In our study, there was no significant association between SM, or SMI and DLT, possibly due to
different body compositions. Among patients with a low VATI, only overweight or obese patients
experienced fewer DLT, whereas normal or underweight patients experienced more DLT. Similarly,
studies have shown the link between a low BMI and chemotherapy-related toxicity [16,17]. However,
there was no significant difference (p = 0.697) between BMI and the probability of DLT in patients with
a low VATI.
We observed inconsistencies when BMI was used as an obesity marker. BMI encompasses several
important parameters, including sarcopenia, VAT, and SAT, which explains some observations. A high
BMI increases the risk of RCC [18]. The relationship between BMI and RCC prognosis remains
controversial, as some studies report a diverse range of associations [19]. To understand how obesity
affects cancer progression and drug-related toxicity, combining the VAT, SAT, and SM parameters is
needed, depending on the cancer type and the patient’s status.
In our study, VATI was a significant predictor of early DLT. Sunitinib is predominantly metabolized
via the liver-based CYP450 enzyme, CYP3A4 [20]. VAT is a strong, independent risk factor for elevated
liver transaminase levels and fatty liver [21], which are associated with decreased CYP3A4 expression
and activity. Therefore, a rise in patients with a DLT and high VAT content is due to the decreased
metabolism of sunitinib via CYP3A4 [22,23]. Subsequently, these patients would have high sunitinib
concentrations, which explains the association between more patients with a DLT and a high VATI.
Future studies are needed to characterize the association between sunitinib pharmacokinetics and VAT
and SM [12].
Five studies have examined VAT effects in patients with localized and advanced disease. Low VAT
content was associated with poor prognosis [24–26]. Another reported no association with overall
mortality [27] and, in the other, the lowest and highest quartiles of VAT percentage were associated
with a higher risk of recurrence [19]. VAT associates with the largest endocrine organ that produces
hormones and cytokines related to cancer progression [28]. VAT releases adipokines, including
adiponectin, that have anti-inflammatory and angiogenesis-inhibiting effects [29]. Low adiponectin
levels correspond with large tumor size and metastasis in RCC, and its levels inversely correlate
with Fuhrman nuclear grades [30]. Adiponectin levels relate more to VAT [31], which supports the
association between a high VATI and prolonged PFS.
Our study had several limitations. Owing to the retrospective nature of our analysis, some results
might be biased, especially as we only evaluated Korean patients. Moreover, we have not documented
and compared medications that might have influenced the pharmacokinetics of sunitinib or DLT.
Studies to validate this finding in other Asian populations are needed.
4. Materials and Methods
4.1. Patients and Ethics
This retrospective review of a multi-institutional prospective cohort study was approved by the
institutional review boards and human research ethics committees of each participating institution
(project no: 4-2020-00528). Among participants in this prospective cohort of patients treated with
cc-mRCC targeted therapy from eight tertiary medical centers in Korea between November 2005 and
November 2019, those treated with first-line sunitinib treatments were evaluated. All the procedures
involving human participants were performed in accordance with institutional and national ethical
standards and the Declaration of Helsinki. For the original prospective cohort study, all the patients
provided informed consent, and the manuscript contains no personal data. The datasets used and/or
analyzed in this study are available from the corresponding author upon reasonable request.
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4.2. Study Design
Adult outpatients with cc-mRCC who received sunitinib at an initial dose of 50 mg per day
according to their Eastern Cooperative Oncology Group performance status and comorbidities, at
the treating physician’s discretion, were included in this study, as previously described [6,9,10,32].
Toxicity profiles were recorded, analyzed, and grouped according to the Common Terminology Criteria
for Adverse Events (CTCAE, v5.0). Toxicity was assessed at each visit every 2 weeks (or before if
clinically indicated) during the first cycle, then monthly, until the discontinuing of the drug. One
treatment cycle was for 6 weeks (4 weeks on and 2 weeks off).
In the case of CTCAE grade 3 or 4 AEs, sunitinib was discontinued, except for grade 3 hypertension,
for which antihypertensives were introduced according to guidelines [33]. Depending on toxicity
resolution, continuation with the initial or decreased dosage or discontinuation was determined at the
treating physician’s discretion.
A DLT was defined as any AEs leading to a dose reduction or the temporary or permanent
discontinuation of treatment. Following the design of a previous study [34], only DLTs occurring
during the first cycle of treatment (6 weeks) were examined. Progression was defined as local recurrence
or distant metastasis, and data on mortality were collected from medical records in the Cancer Registry
Center database at our institution.
4.3. Anthropometry and Body Composition
Weights and heights were recorded during clinical visits according to standard methods,
and recorded values closest to the patient’s computed tomography (CT) scan date were used for
analysis. BMI was calculated (weight (kg)/height2 (m2)) and WHO categories were used: underweight,
BMI < 18.5; normal, BMI between 18.5 and 24.9; overweight, BMI between 25 and 29.9; obese, BMI
> 30 [9,10]. BSA was calculated using the Mosteller formula: BSA (m2) = ((height (cm) × weight
(kg))/3600)1/2 [9,10,35].
CT, for accurate body composition measurements [36,37], was used to assess regional adipose
(visceral and subcutaneous) and muscle tissues. The muscle and adipose tissue values were reported
as total muscle and visceral and subcutaneous fat cross-sectional areas at the third lumbar vertebra (L3)
(cm2) [6,9,10]. The indices used were divided by the patient’s height squared (cm2/m2) to normalize
the values [38].
4.4. Image Analysis
CT images captured near the start of the sunitinib treatment (within 30 days) were considered.
CT scans were excluded if any interventions, such as surgery, that altered body composition occurred
between the CT scan and starting sunitinib treatment. CT images were analyzed using an Aquarius
iNtuition Viewer, v.4.4.12 (TeraRecon). Different body compositions were evaluated using predefined
Hounsfield unit (HU) thresholds. SM was evaluated using thresholds of −29–150 HU [6,9]. For SAT,
−190 to −30 HU was used, and for VAT, −150 to −50 HU was used (Figure 3) [6].
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4.5. Statistical Analyses
Data are presented as the mean± standard deviation or median (interquartile range) for continuous
variables and a percentage for categorical variables. A high VATI was higher than the median VATI
value. For univariate analysis, a Wilcoxon test or Student’s t-test was used to compare continuous
variables, and a chi-square test or Fisher’s exact test was used to compare categorical variables.
Logistic regression analyses were performed for factors predicting early DLTs, including factors that
predicted the occurrence of DLTs at a p < 0.05 upon univariate analysis and ORs with 95% CIs. PFS and
CSS were measured from the first sunitinib administration to the date of disease progression or death.
Kaplan–Meier estimates of the distribution of times from the baseline to outcome were computed,
and groups were compared using the log-rank test. SPSS software v.23.0 (IBM Corp., Armonk, NY,
USA) and GraphPad Prism 8.0 software (GraphPad Software, Inc., La Jolla, CA, USA) were used
for all statistical analyses. All the statistical tests were two-tailed, and p-values less than 0.05 were
statistically significant.
5. Conclusions
In this study, VATI was a significant predictor of sunitinib-associated DLT and survival in patients
with mRCC; those with a low VATI and a BMI greater than23 kg/m2 experienced significantly fewer
DLTs during the first cycle of treatment. Future studies will focus on using sunitinib doses based on
body composition, mainly VATI, to reduce DLT.
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